FDA-APPROVED DOSE AND SCHEDULE

Metastatic
Breast Cancer (MBC)
Metastatic Breast Cancer (MBC)
metastatic breast cancer dosing bottle 260
metastatic breast cancer dosing bottle 260

ILLUSTRATIVE PURPOSES ONLY

  • Administer ABRAXANE once every 3 weeks
  • ABRAXANE is administered intravenously over 30 minutes
  • ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
Advanced Non–Small
Cell Lung Cancer (NSCLC)
Advanced Non–Small Cell Lung Cancer (NSCLC)
non-small cell lung cancer dosing bottles 100 + 6
non-small cell lung cancer dosing bottles 100 + 6

ILLUSTRATIVE PURPOSES ONLY

  • Administer ABRAXANE on Days 1, 8, and 15 of each 21-day cycle
  • Administer carboplatin on Day 1 only of each
    21-day cycle, beginning immediately after the completion of ABRAXANE administration
  • ABRAXANE is administered intravenously over 30 minutes
  • ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
  • Administer ABRAXANE on
    Days 1, 8, and 15 of each
    21-day cycle
  • Administer carboplatin on
    Day 1 only of each 21-day
    cycle, beginning immediately
    after the completion of
    ABRAXANE administration
  • ABRAXANE is administered
    intravenously over 30 minutes
  • ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
Metastatic
Pancreatic Cancer (MPAC)
Metastatic Pancreatic Cancer (MPAC)
metastatic pancreatic cancer dosing bottle 125 + 1000
metastatic pancreatic cancer dosing bottle 125 + 1000

ILLUSTRATIVE PURPOSES ONLY

  • Administer ABRAXANE
    followed by gemcitabine weekly
    for 3 weeks, then 1 week break
    of each 28-day cycle
  • ABRAXANE is administered intravenously over 30-40 minutes
  • ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine
  • Administer ABRAXANE followed by gemcitabine weekly for 3 weeks, then 1 week break of each
    28-day cycle
  • ABRAXANE is administered intravenously over 30-40 minutes
  • ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL